FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

washington, D.C. 205

OMB APPROVAL								
OMB Number: 3235-02								
Estimated average bur	den							
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

				or Se	ction 30(h) of the	e Inves	stment Cor	npany Act o	of 1940							
1. Name and Address of Reporting Person* RA CAPITAL MANAGEMENT, L.P.					2. Issuer Name and Ticker or Trading Symbol Vaxcyte, Inc. [PCVX]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner					
(Last) 200 BER	(Fir	rst) FREET, 18TH	(Middle) FLOOR		3. Date of Earliest Transaction (Month/Day/Year) 09/29/2020 Officer (give title below) Other (specify below)												
(Street) BOSTON	N M.	A	02116	- 4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting Person					n	
(City)	(St	ate)	(Zip)														
			e I - Non-Deriv			1	cquir			-						1	
1. Title of S	Security (Ins	tr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr 8)					nd 5)	5. Amount of Securities Beneficially Owned Following				7. Nature of Indirect Beneficial Ownership (Instr.		
						Code	v	Amount	(A) or (D)	Price		Reported Transaction(s (Instr. 3 and 4		(Instr. 4)	4)	
Common	Stock		09/29/2020			S		80,707	7 D	\$52.	0771(1)	5,408,47	I See Footno				ote(2)(3)(4)
Common	Stock		09/30/2020			S		124,65	6 D	\$50.	2653 ⁽⁵⁾	5,283,81	8	I	I See Footnote ⁽²⁾		ote(2)(3)(4)
Common	Stock		10/01/2020		s 15,967 D \$48.6444 ⁽⁾		6444(6)	\$5,267,85	,851 ⁽⁷⁾			See Footnote ⁽²⁾⁽³⁾⁽⁴					
		Ta	able II - Deriva (e.g., p										d				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	Date (Month/Day/Year) if any (Month/Day/Year) (Month/Day/Year) Execution Date, if any (Month/Day/Year) Securities Expiration Date (Month/Day/Year) E		7. Title and Amount of Securities Underlying Derivative Security (Insti 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		Fo Dir or (I)	vnership rm: ect (D) Indirect (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)						
				Code	v (A) (D)	Da Ex	te ercisable	Expiration Date	Title	Amount or Number of Shares	1					
		Reporting Person															
(Last)		(First)	(Middle)														

(Last)	(First)	(Middle)	
200 BERKEI	LEY STREET, 18T	H FLOOR	
(Street)			
BOSTON	MA	02116	
-			
	(State) dress of Reporting Per Healthcare Fun		
1. Name and Ad	dress of Reporting Per	son* ad LP	
1. Name and Ad RA Capita (Last)	dress of Reporting Per	son* ad LP (Middle)	
1. Name and Ad RA Capita (Last)	dress of Reporting Per I Healthcare Fur (First)	son* ad LP (Middle)	
1. Name and Ad RA Capita (Last) 200 BERKEI	dress of Reporting Per I Healthcare Fur (First)	son* ad LP (Middle)	

(Last)	(First)	(Middle)							
C/O RA CAPITAL MANAGEMENT, L.P.									
200 BERKELE	200 BERKELEY STREET, 18TH FLOOR								
(Street)									
BOSTON	MA	02116							
(City)	(State)	(Zip)							
1. Name and Addr Shah Rajeev	ess of Reporting Person M.	son [*]							
(Last)	(First)	(Middle)							
C/O RA CAPI	C/O RA CAPITAL MANAGEMENT, L.P.								
200 BERKELEY STREET, 18TH FLOOR									
(Street)									
BOSTON	MA	02116							
(City)	(State)	(Zip)							

Explanation of Responses:

- 1. This transaction was executed in multiple trades at prices ranging from \$51.49 to \$53.00; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which these transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.
- 2. RA Capital Management, L.P. (the "Adviser") is the investment manager for the RA Capital Healthcare Fund, L.P. (the "Fund"), the RA Capital Nexus Fund, L.P. (the "Nexus Fund"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah may be deemed indirect beneficial owners of the reported securities for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the "Act").
- 3. They disclaim beneficial ownership of any of the reported securities for the purpose of determining whether they are subject to Section 16 of the Act, however, in reliance on Rule 16a-1(a)(1)(v) and (vii). To the extent that they might be deemed subject to Section 16, they disclaim beneficial ownership of securities held by the Fund and the Nexus Fund for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein, and disclaim any pecuniary interest in securities held in the Account for purposes of Rule 16a-1(a)(2).
- 4. The shares of the Issuer's common stock referenced in the transaction were acquired in the Issuer's initial public offering and were not subject to the restrictions of the lock-up agreement.
- 5. This transaction was executed in multiple trades at prices ranging from \$49.40 to \$51.77; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which these transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.
- 6. This transaction was executed in multiple trades at prices ranging from \$48.01 to \$50.185; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which these transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.
- 7. Includes (a) 3,922,466 shares held by the Fund, (b) 289,545 shares held by the Account, and (c) 1,055,840 shares held by the Nexus Fund.

/s/ Peter Kolchinsky, Manager of RA Capital Management, 10/01/2020 /s/ Peter Kolchinsky, Manager of RA Capital Healthcare GP, LLC, the General Partner of 10/01/2020 RA Capital Healthcare Fund, L.P. /s/ Peter Kolchinsky, 10/01/2020 <u>individually</u> /s/ Rajeev Shah, individually 10/01/2020 ** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.